Evaluation of Volume and Total Nucleated Cell Count as Cord Blood Selection Parameters A Receiver Operating Characteristic Curve Modeling Approach
|
|
- Posy Francis
- 5 years ago
- Views:
Transcription
1 Hematopathology / Umbilical Cord Blood Selection Evaluation of Volume and Total Nucleated Cell Count as Cord Blood Selection Parameters A Receiver Operating Characteristic Curve Modeling Approach José C. Jaime-Pérez, MD, PhD, Roberto Monreal-Robles, MD, Laura N. Rodríguez-Romo, MD, Consuelo Mancías-Guerra, MD, José Luís Herrera-Garza, MD, and David Gómez-Almaguer, MD Key Words: Umbilical cord blood banking; Cord blood selection; CD34+ cord blood cells; Cord blood total nucleated cell content; Cord blood volume; Receiver operating characteristic analysis; Sensitivity; Specificity DOI: /AJCPFB6EXO7BJVLR Abstract The objective of the study was to evaluate the current standard practice of using volume and total nucleated cell (TNC) count for the selection of cord blood (CB) units for cryopreservation and further transplantation. Data on 794 CB units whose CD34+ cell content was determined by flow cytometry were analyzed by using a receiver operating characteristic (ROC) curve model to validate the performance of volume and TNC count for the selection of CB units with grafting purposes. The TNC count was the best parameter to identify CB units having or more CD34+ cells, with an area under the ROC curve of (95% confidence interval, ; P <.01) and an efficiency of 75.4%. Combination of parameters (TNC/mononuclear cells [MNCs], efficiency 74.7%; TNC/volume, efficiency 68.9%; and volume/mncs, efficiency 68.3%) did not lead to improvement in CB selection. All CB units having a TNC count of or more had the required CD34+ cell dose for patients weighing 10 kg or less. Umbilical cord blood (UCB) is used as an alternative source of progenitors for hematopoietic stem cell (HSC) transplantation. Worldwide, more than 450,000 UCB units have been stored in CB banks (CBBs), and more than 10,000 UCB transplants have been performed in children and adults for a variety of disorders, 1 including hematologic malignancies, bone marrow failure syndromes, selected hereditary immunodeficiency states, and metabolic disorders. 2-5 The current status and future trends in this complex and rapidly evolving field have been recently reviewed. 6 HSCs are contained within a population of mononuclear CD34+ antigen-expressing cells, which typically represent fewer than 1% of the total leukocytes in CB. 7 The CD34+ antigen is the accepted marker for determining the HSC content in bone marrow, peripheral blood, and UCB. 8 Although no universally accepted guidelines exist, most CBBs use the combination of product weight (volume) and total nucleated cell (TNC) count as the main selection factors for cryopreservation, requiring a TNC content from 6 to for storage 9 and a minimal volume between 40 and 60 ml The CD34+ cell content has been shown to influence engraftment and survival after unrelated UCB transplantation, better predicting the hematopoietic potential of a CB unit than nucleated cell content. 13 For partially mismatched HLA transplants, the number of CD34+ cells infused is critical, with CD34+ cells per kilogram of the recipient s body weight the threshold dose. 13 Taking into account a 10% to 20% cell loss during freezing-thawing procedures, a dose of CD34+ cells per kilogram of recipient s weight before cryopreservation seems to be more suitable for the selection of CB units for storage. To know the CD34+ cell number in a CB unit could Am J Clin Pathol 2011;136: DOI: /AJCPFB6EXO7BJVLR 721
2 Jaime-Pérez et al / Umbilical Cord Blood Selection be relevant in several aspects, including matching the weight of the intended recipient with the appropriate unit; also, it would allow more precise selection of CB units to perform double-unit transplants for adolescents and adults, as reported. 14 However, owing to the lack of standardization of CD34+ cell counting methods, it is currently not possible to compare CD34+ cell counts among CBBs or transplant centers. Receiver operating characteristic (ROC) curve analysis is a graphic representation of the reciprocal relationship between sensitivity and specificity and provides an objective measure of the overall diagnostic performance of a test; it has been frequently used to compare diagnostic tests. 15,16 We were able to locate only 2 published reports on CB selection using ROC analysis; one focused on obstetric factors to establish selection criteria for CB cryopreservation, 17 and the other dealt with fetal biometry in which prebirth assessment of biparietal diameter might allow the selection of donors who would yield CB units of sufficient volume and cell content. 18 We decided to use formal statistical analysis and ROC curve modeling to analyze the standard practice at most CBBs for using volume and/or the TNC count for the proper selection of suitable CB units for further transplantation. Materials and Methods The characteristics of 794 CB units received between May 2005 and May 2010 at the CBB of the Hematology Department, Dr José E. Gonzalez University Hospital, School of Medicine of the Universidad Autónoma de Nuevo León, Monterrey, México, were retrospectively analyzed for this study. UCB Collection Informed consent for UCB collection was obtained from healthy women with uncomplicated pregnancies receiving care at the Obstetrics Department, University Hospital Dr. José Eleuterio González and other regional hospitals. UCB was collected by gravity into a 150-mL sterile bag collection set (Grifols, Barcelona, Spain), containing 25 ml of citratephosphate-dextrose anticoagulant. The CB unit was then stored on wet ice for transport to the CBB for processing. As do others, 10,11,19 at our CBB, we use volume and the TNC count as criteria for the selection of CB units for cryopreservation. UCB units were analyzed for nucleated cell counts and were cryopreserved if their TNC number was at least and their volume exceeded 80 ml, including the anticoagulant. The time from collection to processing was set at 48 hours or less. Laboratory Processing After removal of aliquots for routine testing, UCB in the collection bag was mixed with 6% hydroxyethyl starch (HES) in a 1:4 ratio, with 30 ml as the maximum. The buffy coat was then separated by centrifuging at 45g for 7 minutes at 10 C according to a method previously described. 20 The UCB/HES mixture and the supernatant plasma were transferred into a second plasma transfer bag without severing the connecting tube. A second centrifugation step was performed at 600g for 15 minutes at 10ºC. The cell suspension was removed into a processing set (Pall Medical, Covina, CA) and adjusted to precisely 20 ml. The equipment used to perform the volume reduction was an automated closed system, Sepax- 100 (Biosafe America, Houston, TX). The cryocyte bag was placed in the Coolmix-210 (Biosafe America), which kept it in constant agitation for adding the cryoprotective mixture, which consists of 2.5 ml of DMSO (dimethyl sulfoxide) 99.9% (Sigma-Aldrich, St Louis, MO) and 2.5 ml of Dextran 40 (Sigma-Aldrich). When the temperature reached 4ºC, the cryocyte bag was placed in a protective aluminum cassette (Medical Technology Vertriebs, Altdorf, Germany) and then deposited horizontally on a level surface inside a controlledrate freezer (Cryomed, Thermo Forma, Marietta, OH) until it reached 90 C. The units were then transferred into the liquid phase of a nitrogen freezer (Cryoplus, Thermo Forma) for long-term storage. Biologic Studies TNC Counting TNC counts were determined with an automated hematology analyzer (Sysmex XT 2000, Sysmex, Mundelein, IL) using a multiangle polarized scatter separation technique, which provides the primary TNC count. The TNC was calculated by multiplying the TNC for the total volume of the bag. The total mononuclear cell (MNC) counts were calculated by adding the absolute count of lymphocytes and monocytes reported in the CBC count and then multiplying this value for the total volume of the bag. CD34+ Cell Counting Before cryopreservation, CD34+ cell counts were determined with the ISHAGE gating strategy 21 using monoclonal antibodies anti-cd45+ fluorescein isothiocyanate (FITC; Becton Dickinson, San Jose, CA) and monoclonal antihuman CD34 class III/FITC, clone BIRMA K-3 (DAKO, Glostrup, Denmark). CD34+ cells were enumerated using a FACSCalibur flow cytometer (Becton Dickinson). Statistical Analysis Normality of the studied variables was assessed with the Kolmogorov-Smirnov test. Spearman correlation set at a significance level of.01 was performed to assess the correlation of volume and TNC and MNC counts with the CD Am J Clin Pathol 2011;136: DOI: /AJCPFB6EXO7BJVLR
3 Hematopathology / Original Article cell content of the CB units. ROC curve analysis was applied to evaluate the performance of volume, TNC count, and absolute MNC counts as a method for identifying CB units with a CD34+ cell content of or more, determining also the optimal operating point allowing the best performance for the CB parameter selected. We arbitrarily added different cutoff points for comparing the performance of the selected parameter at different values, determining their sensitivity, specificity, positive and negative predictive values, efficiency, and positive and negative likelihood ratios The analyzed units were divided in 2 groups depending on a CD34+ cell count, or more or fewer than as determined by flow cytometry. Descriptive statistics (percentages, mean, SD, median, and range) were used to analyze the UCB units group with a count of or more CD34+ cells, presenting the number and total CD34+ cell content of CB units that would be suitable for transplantation based on the required dose of CD34+ cells/kg, estimated for recipients weighing 10 to 40 kg. The statistical package used was SPSS, version 17.0 (SPSS, Chicago, IL). MedCalc statistical software (MedCalc, Mariakerke, Belgium) was used for ROC curve analysis. Results We studied 794 CB units received at our CBB during a 5-year period. By applying the current criteria, we found that our banking efficiency was 57.5%. The initial analysis revealed a direct correlation in volume, absolute TNC and MNC counts, and the total number of CD34+ cells. The TNC content had the most significant correlation with the number of CD34+ cells (r = 0.681; P <.01), compared with the MNC count (r = 0.655; P <.01) and volume (r = 0.581; P <.01). ROC analysis showed the TNC count to be the parameter with a superior area under the ROC curve, (95% confidence interval [CI], ), with a significant difference compared with the MNC count (0.810; 95% CI, ; Table 1 Performance Evaluation for Different ROC-Derived TNC Cutoff Values for Cord Blood Selection Sensitivity Specificity TNC count MNC count Volume Reference line Figure 1 Receiver operating characteristic (ROC) curve analysis comparing the performance of volume (area under the ROC curve [AUC] = 0.784), total nucleated cell (TNC) count (AUC = 0.828), and absolute mononuclear cell (MNC) count (AUC = 0.810) as criteria for selecting cord blood units suitable for cryopreservation. P <.05) and volume (0.784; 95% CI, ; P <.001) Figure 1. There was no significant difference in the area under the ROC curve between volume and MNC count (P =.56). A TNC count of was the optimal operating point chosen by ROC analysis that most accurately allowed for the selection of CB units meeting the CD34+ cell content of (sensitivity, 78.7%; specificity, 70.7%) Table 1 and Figure 2. We also evaluated the performance of combining parameters (TNC/MNC, efficiency 74.7%; TNC/volume, efficiency 68.9%; and volume/mnc, efficiency 68.3%) in the function of their best cutoff values derived from the ROC curve without documenting improved performance on CB selection. TNC Cutoff Value ( 10 8 ) Performance Measure * Sensitivity (%) Specificity (%) Negative predictive value (%) Positive predictive value (%) Efficiency (%) Positive likelihood ratio Negative likelihood ratio ROC, receiver operating characteristic; TNC, total nucleated cell. * Optimal operating point chosen by ROC analysis. Am J Clin Pathol 2011;136: DOI: /AJCPFB6EXO7BJVLR 723
4 Jaime-Pérez et al / Umbilical Cord Blood Selection Sensitivity It is interesting that when applying the ROC-selected TNC cutoff as selection criterion to the 466 CB units having a CD34+ cell content of or more, the CD34+ cell median content increased by 11%, from to , although at the expense of a 21% (n = 99) decrease in the number of CB units available for transplantation. This approach would lead to an increase in the percentage of units stored that could be safely grafted, particularly for patients weighing 15 to 25 kg Table 2 and Figure Specificity Figure 2 Receiver operating characteristic (ROC) curve analysis of absolute total nucleated cell count with an area under the ROC curve of (95% confidence interval, ; P <.01). The optimal ROC-derived cutoff (square) shown has a sensitivity of 78.7% and a specificity of 70.7%. The characteristics of the CB units meeting a CD34+ cell content of or more (n = 466 [58.7%]) were further analyzed. The median volume obtained was ml (range, ml) with a median TNC content of (range, ) and a median CD34+ cell count of (range, ) after volume reduction and before cryopreservation. Based on the requirement of CD34+ cells per kilogram of recipient weight before freezing the CB, this approach would make it possible to use 100%, 37.3%, 15.2%, and 7.5% of CB units for patients weighing 10, 20, 30, or 40 kg, respectively (data not shown). Discussion Although different studies have been performed regarding selection, collection, and processing of CB, 17,26-30 improvement in methods is needed to maximize resource utilization without compromising quality for clinical use, to increase efficacy, and to reduce the cost of CB grafting. The TNC count had the largest area under the ROC curve, confirming that it is the primary driver of the CD34+ cell content in CB. Combining 2 parameters to select CB did not lead to an improvement in the relationship between sensitivity and specificity; therefore, the TNC count as a single criterion seems to be sufficient for selecting CB units for cryopreservation. Most of the CB units not meeting the CD34+ cell content of or more had a TNC count below the ROC-selected value. These units would not have been processed for CD34+ cell content had this cutoff point been applied. It is worth mentioning that of all CB units with a TNC count more than the ROC-selected value, only 20% had a CD34+ cell count of less than These units, however, could potentially be used for double partially HLA-matched UCB transplantation in adults who otherwise are not eligible for allogeneic grafting owing to the lack of a suitable single- UCB unit, as previously reported. 14 Table 2 Descriptive Statistics for Cord Blood Units With a CD34+ Cell Count of or More According to TNC Cutoff Selection Criterion and the Requirement of CD34+ Cells per Kilogram of Patient Weight, Estimated for 10 to 40 kg (n = 466) * CD34+ MNC ( 10 6 ) Patient Weight (kg) TNC Cutoff ( 10 8 ) Mean ± SD Median ± (43.5) 70 (18.6) 35 (9.3) ± (44.4) 70 (19.1) 35 (9.5) ± (48.0) 67 (20.6) 35 (10.8) ± (53.2) 67 (24.1) 35 (12.5) ± (58.9) 64 (27.7) 35 (15.2) ± (60.6) 54 (28.7) 29 (15.4) ± (68.4) 51 (32.9) 27 (17.4) MNC, mononuclear cells; TNC, total nucleated cell. * All units met the required dose for patients weighing 10 kg; 89 units containing CD34+ did not meet the TNC content. For kg, data are given as number (percentage) in relation to the value in the 10-kg column. Optimal operating point chosen by receiver operating characteristic analysis. 724 Am J Clin Pathol 2011;136: DOI: /AJCPFB6EXO7BJVLR
5 Hematopathology / Original Article Patient s Weight (kg) Because CD34+ cell determination demands significant time and resources, we used our data for applying ROC curve analysis to validate current CB parameters as surrogates for CD34+ cell counting and ability to provide reliable, effective, and cost-effective criteria for the appropriate identification of CB units suitable for transplantation, avoiding the cost of processing units with a high probability of not having the required CD34+ cell content for cryopreservation and grafting purposes. We confirmed that the TNC count is the parameter that better correlates with the CD34+ cell content in UCB, in agreement with previous reports. 26,31,32 ROC curve analysis validated the current standard of TNC content of or more as an appropriate cutoff parameter for the selection of CB units containing an adequate number of CD34+ MNCs for cryopreservation for grafting purposes. From the Hematology Department, Internal Medicine Division, Dr. José Eleuterio González University Hospital of the School of Medicine of the Autonomous University of Nuevo León, Monterrey, México. Address reprint requests to Dr Jaime-Pérez: Servicio de Hematología, Hospital Universitario Dr. José E. González, Edificio Dr. Rodrigo Barragán, 2 piso, Avenida Madero y Gonzalitos S/N, Colonia Mitras Centro, Monterrey, Nuevo León, México, CP References 1. Weeks FM, Yee GC, Bartfield AA, et al. The true cost of bone marrow t ransplantation. Am J Med Sci. 1997;314: Wagner JE, Kernan NA, Steinbuch M, et al. Allogeneic sibling umbilical -cord-blood transplantation in children with malignant and non-malignant disease. Lancet. 1995;346: Percentage of Acceptable Cord Blood Units CD34+ cell counting TNC count cutoff Figure 3 Percentage of cord blood units that would be available for transplantation as a function of patient weight using units meeting a CD34+ cell count determined by flow cytometry before cord blood cryopreservation, compared with the application of the parameter total nucleated cell (TNC) count selected by receiver operating characteristic curve analysis. 3. Gluckman E, Rocha V, Boyer-Chammard A, et al, for the Eurocord Transpl ant Group and the European Blood and Marrow Transplantation Group. Outcome of cord-blood transplantation from related and unrelated donors. N Engl J Med. 1997;337: Rubinstein P, Carrier C, Scaradavou A, et al. Outcomes among 562 recip ients of placental-blood transplants from unrelated donors. N Engl J Med. 1998;339: Kurtzberg J, Laughlin M, Graham ML, et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med. 1996;335: McKenna DH, Brunstein CG. Umbilical cord blood: current status and fut ure directions. Vox Sang. 2011;100: Brocklebank AM, Sparrow RL. Enumeration of CD34+ cells in cord blood: a variation on a single-platform flow cytometric method based on the ISHAGE gating strategy. Cytometry. 2001;46: Holyoake TL, Alcorn MJ. CD34+ positive haemopoietic cells: biology and clinical applications. Blood Rev. 1994;8: Solves P, Carbonell-Uberos F, Mirabet V, et al. CD34+ cell content for selecting umbilical cord blood units for cryopreservation. Transfusion. 2007;47: Van Haute I, Lootens N, De Buck K, et al. Selecting cord blood units for storage by CD34+ cell counts. Transfusion. 2005;45: Wu JY, Liao C, Xu ZP, et al. Banking and transplantation of umbilical cord blood in Guangzhou, China. Cytotherapy. 2006;8: Novelo-Garza B, Limon-Flores A, Guerra-Marquez A, et al. Establishing a cord blood banking and transplantation program in Mexico: a single institution experience. Transfusion. 2008;48: Wagner JE, Barker JN, DeFor TE, et al. Transplantation of unrelated d onor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood. 2002;100: Am J Clin Pathol 2011;136: DOI: /AJCPFB6EXO7BJVLR 725
6 Jaime-Pérez et al / Umbilical Cord Blood Selection 14. Barker JN, Weisdorf DJ, DeFor TE, et al. Transplantation of 2 partial ly HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood. 2005;105: Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39: Hanley JA, McNeil BJ. The meaning and use of the area under a receive r operating characteristic (ROC) curve. Radiology. 1982;143: Solves P, Perales A, Mirabet V, et al. Optimizing donor selection in a cord blood bank. Eur J Haematol. 2004;72: Urciuoli P, Passeri S, Ceccarelli F, et al. Pre-birth selection of um bilical cord blood donors. Blood Transfus. 2010;8: Tamburini A, Malerba C, Picardi A, et al. Placental/ umbilical cord bl ood: experience of St. Eugenio Hospital collection center. Transplant Proc. 2005;37: Rubinstein P, Taylor PE, Scaradavou A, et al. Unrelated placental blo od for bone marrow reconstitution: organization of the placental blood program. Blood Cells. 1994;20: Sutherland DR, Anderson L, Keeney M, et al, for the International Soc iety of Hematotherapy and Graft Engineering. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. J Hematother. 1996;5: Akobeng AK. Understanding diagnostic tests 1: sensitivity, specificit y and predictive values. Acta Paediatr. 2007;96: Knottnerus JA, van Weel C, Muris JW. Evaluation of diagnostic procedu res. BMJ. 2002;324: Choi BC. Slopes of a receiver operating characteristic curve and like lihood ratios for a diagnostic test. Am J Epidemiol. 1998;148: Dwyer AJ. In pursuit of a piece of the ROC. Radiology. 1996;201: Jan RH, Wen SH, Shyr MH, et al. Impact of maternal and neonatal facto rs on CD34+ cell count, total nucleated cells, and volume of cord blood. Pediatr Transplant. 2008;12: Hutton EK, Hassan ES. Late vs early clamping of the umbilical cord in full-term neonates: systematic review and meta-analysis of controlled trials. JAMA. 2007;297: Skoric D, Balint B, Petakov M, et al. Collection strategies and cryop reservation of umbilical cord blood. Transfus Med. 2007;17: Meyer TP, Hofmann B, Zaisserer J, et al. Analysis and cryopreservatio n of hematopoietic stem and progenitor cells from umbilical cord blood. Cytotherapy. 2006;8: Koliakos G, Alamdari DH, Tsagias N, et al. A novel highyield volume- reduction method for the cryopreservation of UC blood units. Cytotherapy. 2007;9: Solves P, Perales A, Moraga R, et al. Maternal, neonatal and collecti on factors influencing the haematopoietic content of cord blood units. Acta Haematol. 2005;113: Nakagawa R, Watanabe T, Kawano Y, et al. Analysis of maternal and neonatal factors that influence the nucleated and CD34+ cell yield for cord blood banking. Transfusion. 2004;44: Am J Clin Pathol 2011;136: DOI: /AJCPFB6EXO7BJVLR
Placental and Umbilical Cord Blood as a Source of Stem Cells
Placental and Umbilical Cord Blood as a Source of Stem Cells Policy Number: 7.01.50 Last Review: 12/2018 Origination: 12/2001 Next Review: 12/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue
More informationAldehyde Dehydrogenase Activity as a Marker of Quality in Cryopreserved Cord Blood
Showa Univ J Med Sci 25 4, 297 306, December 2013 Original Aldehyde Dehydrogenase Activity as a Marker of Quality in Cryopreserved Cord Blood Hirokazu IKEDA, Daisuke TOYAMA, Ryosuke MATSUNO, Yoko FUJIMOTO
More informationStudy for the improvement of umbilical cord blood sampling using a new trial apparatus
bs_bs_banner doi:10.1111/jog.12179 J. Obstet. Gynaecol. Res. Vol. 40, No. 2: 405 409, February 2014 Study for the improvement of umbilical cord blood sampling using a new trial apparatus Naoki Masaoka
More informationBMTCN REVIEW COURSE PRE-TRANSPLANT CARE
BMTCN REVIEW COURSE PRE-TRANSPLANT CARE Jennifer Shamai MS, RN, AOCNS, BMTCN Professional Practice Leader Department of Clinical Practice And Professional Education Click How to edit the Master Experts
More informationCord Blood Stem Cell Banking and Transplantation
Cord Blood Stem Cell Banking and Transplantation JOHN W. ADAMSON New York Blood Center, New York, New York, USA Key Words. Cord blood Stem cells Cord blood banking Cord blood transplantation. Cord blood.stern
More informationCorrelation of umbilical cord blood volume with CD34+ cells concentration
IJBTI 2011 ;1 :1 2-1 6. Chandra et al. 1 2 ORIGINAL ARTICLE OPEN ACCESS Correlation of umbilical cord blood volume with CD34+ cells concentration Tulika Chandra, Sheeba Afreen, Ashutosh Kumar, Uma Singh
More informationMedical Policy. MP Placental and Umbilical Cord Blood as a Source of Stem Cells
Medical Policy MP 7.01.50 BCBSA Ref. Policy: 7.01.50 Last Review: 01/30/2018 Effective Date: 01/30/2018 Section: Surgery Related Policies 8.01.20 Hematopoietic Cell Transplantation for Non- Hodgkin Lymphomas
More informationThe number of nucleated cells reflects the hematopoietic content of umbilical cord blood for transplantation
Bone Marrow Transplantation, (1999) 24, 965 970 1999 Stockton Press All rights reserved 0268 3369/99 $15.00 http://www.stockton-press.co.uk/bmt The number of nucleated cells reflects the hematopoietic
More informationOne-Unit versus Two-Unit Cord-Blood Transplantation for Hematologic Cancers
The new england journal of medicine Original Article One-Unit versus Two-Unit Cord-Blood Transplantation for Hematologic Cancers John E. Wagner, Jr., M.D., Mary Eapen, M.B., B.S., Shelly Carter, D.Sc.,
More informationAnalysis of the Viability of Umbilical Cord blood Stem Cells. Sachdeva N
Jsrm/Vol5No.11, 2009 Original Article Analysis of the of Umbilical Cord blood Stem Cells Sachdeva N Dr. Neelam Sachdeva Reader, Department of Zoology, Gargi College, University of Delhi, Siri Fort Road,
More informationCHAPTER 3 LABORATORY PROCEDURES
CHAPTER 3 LABORATORY PROCEDURES CHAPTER 3 LABORATORY PROCEDURES 3.1 HLA TYPING Molecular HLA typing will be performed for all donor cord blood units and patients in the three reference laboratories identified
More informationHaplo vs Cord vs URD Debate
3rd Annual ASBMT Regional Conference for NPs, PAs and Fellows Haplo vs Cord vs URD Debate Claudio G. Brunstein Associate Professor University of Minnesota Medical School Take home message Finding a donor
More informationCord Blood Bankers are. Angie Yost, MT(ASCP) CM 2016 ASCLS-MO CLMA Spring Meeting
Cord Blood Bankers are Angie Yost, MT(ASCP) CM 2016 ASCLS-MO CLMA Spring Meeting Objectives Cord blood 101 Manufacturing and cryopreservation Characterization testing Why Do We Need Cord Blood? Each year,
More informationApplications of Cord Blood Stem Cells
Applications of Cord Blood Stem Cells over 360 families have used their banked cord blood in transplant or regenerative medicine research. 1 88 ViaCord has released over 360 units for transplant or infusion
More informationUmbilical Cord Blood Transplantation
Umbilical Cord Blood Transplantation Current Results John E. Wagner, M.D. Blood and Marrow Transplant Program and Stem Cell Institute University of Minnesota Donor Choices Unrelated Marrow/PBSC Results
More informationA Review of Procedures Involved in Human Umbilical Cord Blood Banking and Transplantation
REVIEW ARTICLE IJBC 2014; 7(1): Downloaded from ijbc.ir at 18:16 +0330 on Sunday January 13th 2019 A Review of Procedures Involved in Human Umbilical Cord Blood Banking and Transplantation Nikougoftar
More informationClinical Use of Umbilical Cord Blood Hematopoietic Stem Cells
Biology of Blood and Marrow Transplantation 12:34-41 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1201-0107$32.00/0 doi:10.1016/j.bbmt.2005.09.006 Clinical Use of Umbilical
More informationHSCT MANAGEMENT WHITE PAPER. Managing stem cell apheresis effectively
HAEMATOLOGY JANUARY 2017 WHITE PAPER HSCT MANAGEMENT Managing stem cell apheresis effectively Haematopoietic stem cell transplantation Haematopoietic stem cell transplantation (HSCT) is a treatment that
More informationResearch Article Mean Platelet Volume Reflect Hematopoietic Potency and Correlated Blood Group O in Cord Blood from Healthy Newborn
BioMed Volume 2013, Article ID 754169, 4 pages http://dx.doi.org/10.1155/2013/754169 Research Article Mean Platelet Volume Reflect Hematopoietic Potency and Correlated Blood Group O in Cord Blood from
More informationWhat the Transfusion Scientist should know about Stem Cells. Dr Claire Wiggins BBTS September 2017
What the Transfusion Scientist should know about Stem Cells Dr Claire Wiggins BBTS September 2017 What is a stem cell? Undifferentiated cell Can divide and self renew for long periods Differentiate into
More informationOneMatch Stem Cell and Marrow Network. Training Guide
OneMatch Stem Cell and Marrow Network Training Guide What is OneMatch all about? OneMatch is a Canadian Program that matches and coordinates the collection of stem cells from potential donors to help save
More informationREVIEW ARTICLE. Umbilical Cord Blood Transplantation: Where Do We Stand? ASBMT BB&MT. Raymond C. Wadlow, David L. Porter
Biology of Blood and Marrow Transplantation 8:637-647 (2002) 2002 American Society for Blood and Marrow Transplantation ASBMT REVIEW ARTICLE Umbilical Cord Blood Transplantation: Where Do We Stand? Raymond
More informationHematopoiesis i starts from. HPC differentiates t to sequentially more mature. HPC circulate in very low
Upstate Cord Blood Bank Hematopoietic Progenitor Cells Hematopoiesis i starts from self renewing HPC HPC differentiates t to sequentially more mature blood cells HPC circulate in very low numbers in adults
More informationAnalysis of Hematopoietic Cell Transplants Using Plasma-Depleted Cord Blood Products That Are Not Red Blood Cell Reduced
Biology of Blood and Marrow Transplantation 13:1346-1357 (2007) 2007 American Society for Blood and Marrow Transplantation 1083-8791/07/1311-0001$32.00/0 doi:10.1016/j.bbmt.2007.07.012 Analysis of Hematopoietic
More informationPeripheral blood stem cells Number of viable CD34 + cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation
(22) 29, 967 972 22 Nature Publishing Group All rights reserved 268 3369/2 $25. www.nature.com/bmt Peripheral blood stem cells Number of viable CD34 + cells reinfused predicts engraftment in autologous
More informationNIH Public Access Author Manuscript Lancet Oncol. Author manuscript; available in PMC 2011 August 29.
NIH Public Access Author Manuscript Published in final edited form as: Lancet Oncol. 2010 July ; 11(7): 653 660. doi:10.1016/s1470-2045(10)70127-3. Effect of Graft Source on Unrelated Donor Haemopoietic
More informationSECOND ANNUAL INTERNATIONAL UMBILICAL CORD BLOOD SYMPOSIUM
Biology of Blood and Marrow Transplantation 10:728-739 (2004) 2004 American Society for Blood and Marrow Transplantation 1083-8791/04/1010-0009$30.00/0 doi:10.1016/j.bbmt.2004.06.010 SECOND ANNUAL INTERNATIONAL
More informationGraft source and Stem cell collection SULADA PUKIAT, MD
+ Graft source and Stem cell collection SULADA PUKIAT, MD + Hematopoietic stem cells Hematopoietic stem cells are CD34 + /CD45 dim /SSC low /FSClow to intermediate Neutrophils Bone NK cells T cells Basophils
More informationCord Blood Banking. The Birth of a New Field
FEATURE Karen Titus Cord Blood Banking The Birth of a New Field iven the great availability of cord blood every new birth represents a possible source it's little wonder this blood product has drawn intense
More informationThe National Marrow Donor Program. Graft Sources for Hematopoietic Cell Transplantation. Simon Bostic, URD Transplant Recipient
1988 199 1992 1994 1996 1998 2 22 24 26 28 21 212 214 216 218 Adult Donors Cord Blood Units The National Donor Program Graft Sources for Hematopoietic Cell Transplantation Dennis L. Confer, MD Chief Medical
More informationMadrid Cord Blood Bank, b Department of Hematology, c Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain
Original Article A Modified Cord Blood Collection Method Achieves Sufficient Cell Levels for Transplantation in Most Adult Patients Rafael Bornstein, a,b Ana I. Flores, a M. Angeles Montalbán, b Manuel
More informationProtocol Number: 10-CBA National Clinical Trial (NCT) Identified Number: NCT
A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications
More informationDr.PSRK.Sastry MD, ECMO
Peripheral blood stem cell transplantation (Haematopoietic stem cell transplantation) Dr.PSRK.Sastry MD, ECMO Consultant, Medical Oncology Kokilaben Dhirubhai Ambani Hospital Normal hematopoiesis Historical
More informationOriginal article. Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 2
Original article http://dx.doi.org/1.3345/kjp.212.55.3.93 Korean J Pediatr 212;55(3):93-99 Hematopoietic stem cell transplantation in children with acute leukemia: similar outcomes in recipients of umbilical
More informationA Meta-Analysis of Unrelated Donor Umbilical Cord Blood Transplantation versus Unrelated Donor Bone Marrow Transplantation in Acute Leukemia Patients
A Meta-Analysis of Unrelated Donor Umbilical Cord Blood Transplantation versus Unrelated Donor Bone Marrow Transplantation in Acute Leukemia Patients Haoran Zhang, Junmin Chen, Wenzhong Que Umbilical cord
More information& 2007 Nature Publishing Group All rights reserved /07 $
() 9, & Nature Publishing Group All rights reserved 8-9/ $. www.nature.com/bmt ORIGINAL ARTICLE The impact of post-thaw colony-forming units-granulocyte/macrophage on engraftment following unrelated cord
More informationQuality rather than quantity: the cord blood bank dilemma
(2010) 45, 970 978 & 2010 Macmillan Publishers Limited All rights reserved 0268-3369/10 $32.00 www.nature.com/bmt REVIEW Quality rather than quantity: the cord blood bank dilemma S Querol 1,2, SG Gomez
More informationTeja Falk Radke, 1 David Barbosa, 1 Richard Charles Duggleby, 2,3 Riccardo Saccardi, 4,5 Sergio Querol, 2,6 and Gesine Kögler 1. 1.
Stem Cells International Volume 213, Article ID 823912, 1 pages http://dx.doi.org/1.1155/213/823912 Research Article The Assessment of Parameters Affecting the Quality of Cord Blood by the Appliance of
More informationUmbilical cord blood transplantation for acute myeloid leukemia Anjali S. Advani a and Mary J. Laughlin b
Umbilical cord blood transplantation for acute myeloid leukemia Anjali S. Advani a and Mary J. Laughlin b a The Cleveland Clinic Lerner College of Medicine, Department of Hematologic Oncology and Blood
More informationHaploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017
Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017 Allogeneic Transplant Recipients in the US, by Donor Type 9000
More informationEBMT Complications and Quality of Life Working Party Educational Course
EBMT Complications and Quality of Life Working Party Educational Course Organisers: R. Duarte, G. Basak 23-24 October 2014, Warsaw, Poland #EBMT2014 www.ebmt.org EBMT Complications and Quality of Life
More informationStatus of umbilical cord blood transplantation in the year 2001
428 J Clin Pathol 2001;54:428 434 Status of umbilical cord blood transplantation in the year 2001 JMHows Abstract Umbilical cord blood (UCB) transplantation is limited to small recipients because of the
More informationThe Texas Medical Center
ISCT Regional Meeting November 2 4, 2007 Cryopreservation - Evaluation of Different Processes Presenters: Carlos Lee & Renee Smilee The Texas Medical Center Center for Cell & Gene Therapy The Feigin Center
More informationjournal of medicine The new england Outcomes after Transplantation of Cord Blood or Bone Marrow from Unrelated Donors in Adults with Leukemia abstract
The new england journal of medicine established in 1812 november 25, 2004 vol. 351 no. 22 Outcomes after Transplantation of Cord Blood or Bone Marrow from Unrelated Donors in Adults with Leukemia Mary
More informationCustomer Information Literature List Platelets
Customer Information Literature List Platelets Date: August 2015 Subject: Literature List Platelets Issued by: Scientific Customer Services Number: 150803 Note: Whether references are given in British
More informationBoth AABB and the Foundation for the Accreditation
TRANSPLANTATION AND CELLULAR ENGINEERING Use of allogeneic apheresis stem cell products as an interlaboratory proficiency challenge Laura Cooling, 1 Kelly Roxbury, 1 Sandra Hoffmann, 1 Joan DeBusscher,
More informationTelephone: ; Fax: ; E mail:
MINUTES AND OVERVIEW PLAN CIBMTR WORKING COMMITTEE FOR GRAFT SOURCES & MANIPULATION Grapevine, TX Thursday, February 27, 2014, 2:45 4:45 pm Co Chair: Co Chair: Co Chair: Statisticians: Scientific Director:
More informationPaola Di Ciaccio Vanja Nikolac
Paola Di Ciaccio Vanja Nikolac ITALYintheHSCfield:HOWISTHISRULED? Directive 2004/23/EC of the European Parliament and of the Council of 31March2004 on setting standards of quality and safety for the donation,
More informationThe role of HLA in Allogeneic Hematopoietic Stem Cell Transplantation and Platelet Refractoriness.
The role of HLA in Allogeneic Hematopoietic Stem Cell Transplantation and Platelet Refractoriness. Robert Liwski, MD, PhD, FRCPC Medical Director HLA Typing Laboratory Department of Pathology Dalhousie
More informationFederica Galaverna, 1 Daria Pagliara, 1 Deepa Manwani, 2 Rajni Agarwal-Hashmi, 3 Melissa Aldinger, 4 Franco Locatelli 1
Administration of Rivogenlecleucel (Rivo-cel, BPX-501) Following αβ T- and B-Cell Depleted Haplo-HSCT in Children With Transfusion-Dependent Thalassemia Federica Galaverna, 1 Daria Pagliara, 1 Deepa Manwani,
More informationApplications for the MACSQuant Analyzer *
For research use only Enumeration of CD34/CD133 positive cells with the CD34/CD133 Enumeration Kit Applications for the MACSQuant Analyzer * Background The CD34 antigen is a single-chain transmembrane
More informationUMBILICAL CORD BLOOD STEM CELLS EXPANDED IN THE PRESENCE OF NICOTINAMIDE (NICORD) PROVIDE LONG TERM MULITI-LINEAGE ENGRAFTMENT
UMBILICAL CORD BLOOD STEM CELLS EXPANDED IN THE PRESENCE OF NICOTINAMIDE (NICORD) PROVIDE LONG TERM MULITI-LINEAGE ENGRAFTMENT Mitchell E. Horwitz, MD Duke University Medical Center Duke Cancer Institute
More informationHHS Public Access Author manuscript Bone Marrow Transplant. Author manuscript; available in PMC 2015 July 01.
KIR and HLA genotypes have no identifiable role in single unit dominance following double unit umbilical cord blood transplantation Nidale Tarek 1,6, Meighan M. Gallagher 2,7, Joanne F. Chou 3, Marissa
More informationObjectives. Cord Blood is RelaOvely Recent Technology BMT Pharmacists Conference: Debate - Haploidentical vs. Umbilical Cord Blood Transplant
214 BMT Pharmacists Conference: Debate - Haploidentical vs. Umbilical Cord Blood Transplant Claudio G Brunstein Associate Professor of Medicine University of Minnesota Minneapolis, MN Objectives Defend
More informationBlood and Marrow Transplant (BMT) for Sickle Cell Disease
Blood and Marrow Transplant (BMT) for Sickle Cell Disease Rhiannon is now cured of sickle cell disease after BMT. Blood and marrow transplant (BMT) is a proven cure for sickle cell disease. This handbook
More informationHEMATOPOIETIC ENGRAFTMENT IN ADULT RECIPIENTS OF UMBILICAL-CORD BLOOD FROM UNRELATED DONORS
HEMATOPOIETIC ENGRAFTMENT IN ADULT RECIPIENTS OF UMBILICAL-CORD BLOOD FROM UNRELATED DONORS HEMATOPOIETIC ENGRAFTMENT AND SURVIVAL IN ADULT RECIPIENTS OF UMBILICAL-CORD BLOOD FROM UNRELATED DONORS MARY
More informationHematopoietic Engraftment in Recipients of Unrelated Donor Umbilical Cord Blood Is Affected by the CD34 and CD8 Cell Doses
Biology of Blood and Marrow Transplantation 13:822-830 (2007) 2007 American Society for Blood and Marrow Transplantation 1083-8791/07/1307-0001$32.00/0 doi:10.1016/j.bbmt.2007.03.006 Hematopoietic Engraftment
More informationPotency & Release Testing for unrelated donor cord blood units
Potency & Release Testing for unrelated donor cord blood units Joanne Kurtzberg, MD Robertson Cell and Translational Therapy Program Pediatric Blood and Marrow Transplant Program Carolinas Cord Blood Bank
More informationAbout OMICS Group Conferences
About OMICS Group OMICS Group International is an amalgamation of Open Access publications and worldwide international science conferences and events. Established in the year 2007 with the sole aim of
More informationKEY WORDS: Hematopoietic stem cell mobilization, Granulocyte colony-stimulating factor, Healthy donor, Apheresis
Factors Associated with Peripheral Blood Stem Cell Yield in Volunteer Donors Mobilized with Granulocyte Colony-Stimulating Factors: The Impact of Donor Characteristics and Procedural Settings Tso-Fu Wang,
More informationStem Cell Transplantation for Severe Aplastic Anemia
Number of Transplants 10/24/2011 Stem Cell Transplantation for Severe Aplastic Anemia Claudio Anasetti, MD Professor of Oncology and Medicine Chair, Blood and Marrow Transplant Dpt Moffitt Cancer Center
More informationEvaluation of Early Post-transplant Leukocyte Recovery Using the Undiluted Erythrocyte Lysing Technique
Annals of Clinical & Laboratory Science, vol. 32, no. 2, 2002 159 Evaluation of Early Post-transplant Leukocyte Recovery Using the Undiluted Erythrocyte Lysing Technique Myungshin Kim, 1 Ja Young Kim,
More informationWhat s a Transplant? What s not?
What s a Transplant? What s not? How to report the difference? Daniel Weisdorf MD University of Minnesota Anti-cancer effects of BMT or PBSCT [HSCT] Kill the cancer Save the patient Restore immunocompetence
More informationCarlos Bachier, Josh Potter, Grant Potter, Rominna Sugay, Paul Shaughnessy, Kawah Chan, Veronica Jude, Renee Madden, Charles F.
High White Blood Cell Concentration in the Peripheral Blood Stem Cell Product Can Induce Seizures during Infusion of Autologous Peripheral Blood Stem Cells Carlos Bachier, Josh Potter, Grant Potter, Rominna
More informationCord Blood Transplant. E. Gluckman Eurocord ESH-EBMT training course Vienna 2014
Cord Blood Transplant E. Gluckman Eurocord ESH-EBMT training course Vienna 2014 Background Since 1988, umbilical cord blood (CB) has been successfully used to treat children and adults needing stem cell
More informationClinical Policy: Donor Lymphocyte Infusion
Clinical Policy: Reference Number: PA.CP.MP.101 Effective Date: 01/18 Last Review Date: 11/16 Coding Implications Revision Log This policy describes the medical necessity requirements for a donor lymphocyte
More informationUse of alternative donors in HSCT (Europe)
Use of alternative donors in HSCT (Europe) Passweg JR, Baldomero H, Bader P et al (2015) Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors
More informationUnrelated Donor StemCell Transplantation: The Role of the National Marrow Donor Program
Unrelated Donor StemCell Transplantation: The Role of the National Marrow Donor Program August 01, 2003 Palliative and Supportive Care [1], Oncology Journal [2] By Chatchada Karanes, MD [3], Dennis Confer,
More informationTHIRD ANNUAL INTERNATIONAL UMBILICAL CORD BLOOD TRANSPLANTATION SYMPOSIUM
Biology of Blood and Marrow Transplantation 11:921-927 (2005) 2005 American Society for Blood and Marrow Transplantation 1083-8791/05/1111-0009$30.00/0 doi:10.1016/j.bbmt.2005.08.028 THIRD ANNUAL INTERNATIONAL
More informationCELLULAR THERAPY QUIZ. Correct answers and rationale
CELLULAR THERAPY QUIZ Correct answers and rationale In January 2018, registered cellular therapy (CT) facilities were asked to participate in the quiz to determine the educational needs of the users regarding
More informationD7.1 Report summarising results of survey of EU countries to identify volumes and trends in relation to the import and export of stem cells
Disclaimer: The content of this Deliverable represents the views of the author only and is his/her sole responsibility; it cannot be considered to reflect the views of the European Commission and/or the
More informationD7.1 Report summarising results of survey of EU countries to identify volumes and trends in relation to the import and export of stem cells
Disclaimer: The content of this Deliverable represents the views of the author only and is his/her sole responsibility; it cannot be considered to reflect the views of the European Commission and/or the
More informationXM-ONE XM-ONE XM-ONE. References XMO_V4.0_100205_CE.EU
Transplantation Cross match Transplantation Cross match XMO_V4._125_CE.EU Manufactured by: ABSORBER AB Address: Drottninggatan 33 SE-13 95 Stockholm, Sweden E-mail: info-ssp@olerup.com Tel: +46 8 5 89
More informationStem cell transplantation for haemoglobinopathies. Dr P J Darbyshire Birmingham Childrens Hospital
Stem cell transplantation for haemoglobinopathies Dr P J Darbyshire Birmingham Childrens Hospital Survival by Cohort of Birth (N=977) 1.00 85-97 80-84 75-79 70-74 0.75 Survival Probability 0.50 0.25 P
More informationCord blood transplantation and stem cell regenerative potential
Experimental Hematology 2011;39:393 412 Cord blood transplantation and stem cell regenerative potential Yanling Liao a, Mark B. Geyer a, Albert J. Yang a, and Mitchell S. Cairo a,b,c a Department of Pediatrics,
More informationAutologous peripheral blood stem cells (PBSC)
998; 83-6 9-3-25 9:27 Pagina 489 Haematologica 998; 83:489-495 original paper C D 3 4 + cell dose and CD33 subsets: collection and engraftment kinetics in autologous peripheral blood stem cells tra n s
More informationTransplantation - Challenges for the future. Dr Gordon Cook S t James s Institute of Oncology, Leeds Teaching Hospitals Trust
Transplantation - Challenges for the future Dr Gordon Cook S t James s Institute of Oncology, Leeds Teaching Hospitals Trust Bone Marrow Transplantation Timeline, 1957-2006 Appelbaum F. N Engl J Med 2007;357:1472-1475
More informationNational Marrow Donor Program HLA-Matching Guidelines for Unrelated Marrow Transplants
Biology of Blood and Marrow Transplantation 9:610-615 (2003) 2003 American Society for Blood and Marrow Transplantation 1083-8791/03/0910-0003$30.00/0 doi:10.1016/s1083-8791(03)00329-x National Marrow
More informationBiol Blood Marrow Transplant 19 (2013) 156e160
Biol Blood Marrow Transplant 19 (2013) 156e160 Correlation of Infused CD3 þ CD8 þ Cells with Single-Donor Dominance after Double-Unit Cord Blood Transplantation Filippo Milano 1, *, Shelly Heimfeld 1,2,
More informationDepartment of Pharmacy, Georgia Health Sciences University, Augusta, GA, USA 3
Oncology Volume 2012, Article ID 931071, 5 pages doi:10.1155/2012/931071 Research Article Plerixafor Salvage Is Safe and Effective in Hard-to-Mobilize Patients Undergoing Chemotherapy and Filgrastim-Based
More informationGVHD. URD unrelated donor
1 GVHD T-B GVHD 1 RDrelated donor URDunrelated donor 2. Julie M. Vose and Steven Z. Pavletic. Haematopoietic Stem Cell Transplantation. In Goldman: Cecil Medicine, 23 rd ed.; chapter 184 (Saunders, An
More informationAutologous hematopoietic stem cell (HSC)
TRANSPLANTATION AND CELLULAR ENGINEERING Adverse events of cryopreserved hematopoietic stem cell infusions in adults: a single-center observational study Zaher K. Otrock, Diane S. Sempek, Sherry Carey,
More informationCryoStor CS2, CS5 and CS10 FREEZE MEDIA
CryoStor CS2, CS5 and CS10 FREEZE MEDIA Pre-Formulated Serum-Free Protein-Free cgmp Manufactured FDA Master File Sterility, Endotoxin, and Cell-Based Release Testing CryoStor, a series of cell-specific,
More informationGetting Beyond the Flags: Quantitative assessment of immature granulocyte (IG) populations may improve the assessment of sepsis and inflammation.
Getting Beyond the Flags: Quantitative assessment of immature granulocyte (IG) populations may improve the assessment of sepsis and inflammation. Sysmex America White Paper One Nelson C. White Parkway,
More informationSickle Cell Diseasechronic. curable disease? Objectives. Why would a family ask about cure for SCD?
Sickle Cell Diseasechronic illness or curable disease? Gregory M.T. Guilcher MD, FRCPC, FAAP Objectives To review the general principles of hematopoietic stem cell transplantation (HSCT), including risks
More informationHLA Match Likelihoods for Hematopoietic Stem-Cell Grafts in the U.S. Registry
The new england journal of medicine special article HLA Likelihoods for Hematopoietic Stem-Cell Grafts in the U.S. Registry Loren Gragert, B.S., B.A., Mary Eapen, M.B., B.S., Eric Williams, Ph.D., John
More informationIt has been widely accepted that cryopreservation
Haematologica 1998; 83:1001-1005 original paper Controlled- versus uncontrolled- cryopreservation of peripheral blood progenitor cells: a prospective multicenter study JAIME PEREZ-OTEYZA, * RAFAEL BORNSTEIN,
More informationHuman Umbilical Cord Blood CD34 + /133+ Progenitor Cell Care Manual
Human Umbilical Cord Blood CD34 + /133+ Progenitor Cell Care Manual INSTRUCTION MANUAL ZBM0065.04 SHIPPING CONDITIONS Human Umbilical Cord Blood CD34+/133+ Progenitor Cells, cryopreserved Cryopreserved
More informationJ.A. García Vela a,, I. Delgado a, R. Bornstein b, B. Alvarez a, M.C.Auray b, I. Martin a, F.Oña a and F. Gilsanz b
93 Comparative intracellular cytokine production by in vitro stimulated T lymphocytes from human umbilical cord blood (HUCB) and adult peripheral blood (APB) J.A. García Vela a,, I. Delgado a, R. Bornstein
More informationISCT Workshop #7 Perspectives in Cell Selection Immunomagnetic Selection
ISCT Workshop #7 Perspectives in Cell Selection Immunomagnetic Selection Carolyn A. Keever-Taylor, PhD Medical College of Wisconsin June 7, 2012 History of Available Devices CellPro CEPRATE Avidin/Biotin
More informationThe Journal of International Medical Research 2011; 39:
The Journal of International Medical Research 2011; 39: 934 943 Comparative Evaluation of the Microcolumn Gel Card Test and the Conventional Tube Test for Measurement of Titres of Immunoglobulin G Antibodies
More informationHematopoietic Stem Cell Transplant in Sickle Cell Disease- An update
Hematopoietic Stem Cell Transplant in Sickle Cell Disease- An update Dr Chirag A Shah Diplomate American Board of Hematology and Medical Oncology Director, Dept of Hemato-Oncology and Stem Cell Transplant
More informationReview Article. Umbilical cord blood transplantation: the first 25 years and beyond. Introduction. Scientific basis of cord blood transplantation
Review Article Umbilical cord blood transplantation: the first 25 years and beyond Karen K. Ballen, 1 Eliane Gluckman, 2 and Hal E. Broxmeyer 3 1 Massachusetts General Hospital Cancer Center, Boston, MA;
More informationXIV. HLA AND TRANSPLANTATION MEDICINE
XIV. HLA AND TRANSPLANTATION MEDICINE A. Introduction 1. The HLA system includes a complex array of genes and their molecular products that are involved in immune regulation and cellular differentiation.
More informationIntroduction 6/7/2013. Umbilical Cord Blood Transplantation: Research and Clinical Applications
Umbilical Cord Blood Transplantation: Research and Clinical Applications Omar Aljitawi, MD Hematology/Oncology Pathology and Laboratory Medicine University of Kansas Medical Center April 27, 13 Introduction
More informationSterility Testing of Peripheral Blood Stem cell (PBSC) harvests in a Tertiary Oncology Setup
Sterility Testing of Peripheral Blood Stem cell (PBSC) harvests in a Tertiary Oncology Setup Bankar S 1, Tirlotkar A 1, Ojha S 1, Bhat V 2,Kannan S 3, Rajadhyaksha S 1 1. Department of Transfusion Medicine,
More informationIN UTERO HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CANINES: THE GESTATIONAL WINDOW OF OPPORTUNITY TO MAXIMIZE ENGRAFTMENT
IN UTERO HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CANINES: THE GESTATIONAL WINDOW OF OPPORTUNITY TO MAXIMIZE ENGRAFTMENT Karin J. Blakemore, M.D. Division of Maternal-Fetal Medicine The Bone Marrow Transplant
More informationCord-Blood Transplantation in Patients with Minimal Residual Disease
The new england journal of medicine Original Article Cord-Blood Transplantation in Patients with Minimal Residual Disease Filippo Milano, M.D., Ph.D., Ted Gooley, Ph.D., Brent Wood, M.D., Ann Woolfrey,
More informationMore than 30 years ago it was demonstrated
TRF 0 TRANSPLANTATION AND CELLULAR ENGINEERING Establishing a cord blood banking and transplantation program in Mexico: a single institution experience Barbara Novelo-Garza, Alejandro Limon-Flores, Angel
More informationFactors Influencing Haematopoietic Progenitor cell transplant outcome Optimising donor selection
Factors Influencing Haematopoietic Progenitor cell transplant outcome Optimising donor selection Alison Logan Transplantation Laboratory Manchester Royal Infirmary Haematopoietic progenitor cell transplants
More information